// App-Quantinova.ai

[SAT0355] : RISK AND CHARACTERISTICS OF DRUG INDUCED VASCULITIS IN PATIENTS EXPOSED TO TUMOUR NECROSIS FACTOR ? INHIBITOR THERAPY: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS

Researchers

Presenter

  • M. Jani

Principal Investigators

  • W. Dixon

  • L. Kearsley-Fleet

  • I. Bruce

  • H. Chinoy

  • A. Barton

  • M. Lunt

  • D. Symmons

  • K. Hyrich

Medical Centers

  • Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Leukocytoclastic vasculitis

  • Venous thrombosis

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • Bisacodyl

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved